These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ; Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844 [TBL] [Abstract][Full Text] [Related]
44. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Björkman S; Folkesson A; Berntorp E Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717 [TBL] [Abstract][Full Text] [Related]
45. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study. Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056 [TBL] [Abstract][Full Text] [Related]
46. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital. Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601 [TBL] [Abstract][Full Text] [Related]
48. Low bone mass and hypovitaminosis D in haemophilia: A single-centre study in patients with severe and moderate haemophilia A and B. Linari S; Melchiorre D; Pieri L; Tofani L; Fanelli A; Brogi M; Castaman G Haemophilia; 2020 Sep; 26(5):898-906. PubMed ID: 32842167 [TBL] [Abstract][Full Text] [Related]
49. Surgery in haemophilic patients with inhibitors. Rodriguez-Merchan EC Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039 [No Abstract] [Full Text] [Related]
50. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits]. Roosendaal G; Lafeber FP Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260 [TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. Quon DV; Logan L Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876 [TBL] [Abstract][Full Text] [Related]
53. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Ahnström J; Berntorp E; Lindvall K; Björkman S Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163 [TBL] [Abstract][Full Text] [Related]
54. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B. Orstavik KH; Scheibel E; Ingerslev J; Schwartz M Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150 [TBL] [Abstract][Full Text] [Related]
55. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Zappa S; McDaniel M; Marandola J; Allen G Haemophilia; 2012 May; 18(3):e140-53. PubMed ID: 22533455 [TBL] [Abstract][Full Text] [Related]
56. Risk factors associated with inhibitor development in Chinese patients with haemophilia B. Zhou J; Ding Q; Chen Z; Yang H; Lin L; Wang H; Wang X; Wu R Haemophilia; 2015 Jul; 21(4):e286-93. PubMed ID: 25929987 [TBL] [Abstract][Full Text] [Related]
57. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients]. Briët E; Mauser-Bunschoten EP Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158 [TBL] [Abstract][Full Text] [Related]
58. Haemophilia B: impact on patients and economic burden of disease. Gater A; Thomson TA; Strandberg-Larsen M Thromb Haemost; 2011 Sep; 106(3):398-404. PubMed ID: 21833450 [TBL] [Abstract][Full Text] [Related]
59. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B. Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Cabrera N; Aznar JA; Woodward MK; Páez A Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747 [TBL] [Abstract][Full Text] [Related]
60. A post hoc comparative real-world analysis of HEAD-US score for joint health assessment of patients with severe haemophilia A and B in Spain. Álvarez-Román MT; Jiménez-Yuste V; Martín-Salces M; De la Corte-Rodríguez H; Bonanad S; Núñez R; Fernández-Mosteirín N; García-Frade LJ; Martinoli C; Kim HK Haemophilia; 2024 Mar; 30(2):513-522. PubMed ID: 38282205 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]